NASDAQ$SCPH
scPharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
scPharmaceuticals reported second quarter 2022 financial results and provided a business update.
scPharmaceuticals announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022. The company ended the second quarter with $56.0 million in cash, cash equivalents, restricted cash and investments. scPharmaceuticals reported a net loss of $9.7 million for the second quarter of 2022.
- FDA accepted FUROSCIX NDA with a PDUFA target action date of October 8, 2022.
- Advanced commercial readiness activities in anticipation of a Q4 2022 commercial launch of FUROSCIX, if approved.
- Announced positive results from the AT HOME-HF Phase 2 Pilot study, showing a 37% reduction in heart failure hospitalization risk with FUROSCIX.
- Ended Q2 with cash, cash equivalents, restricted cash and investments of $56.0 million.
Headline financials
Revenue & EPS history
scPharmaceuticals · Revenue · Quarterly
$16M
Revenue by segment
scPharmaceuticals · $3.8M total across 1 segment · Q3 2023
- FUROSCIX$3.8M—100.0%
Forward guidance
The Company forecasts its 2022 net loss to be $43 to $48 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+3.8%
Avg return
Earnings day
+5.8%
Avg return
5 days after
+7.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+52.7%
Q4 2019
Best reaction
-14.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -7.4% | -4.6% | +11.6% | |
| Q1 2025 | +27.4% | +45.1% | +74.8% | |
| Q4 2024 | -1.0% | -1.3% | -15.5% | |
| Q3 2024 | -14.5% | -14.8% | -18.6% | |
| Q2 2024 | +2.6% | +3.7% | +11.8% | |
| Q1 2024 | +5.1% | +10.6% | -6.9% | |
| Q4 2023 | -1.1% | +2.2% | -7.8% | |
| Q3 2023 | -8.4% | — | — | |
| Q2 2023 | +0.0% | — | — | |
| Q1 2023 | -0.6% | — | — | |
| Q4 2022 | +25.0% | — | — | |
| Q3 2022 | +7.3% | — | — | |
| Q2 2022 | +8.6% | — | — | |
| Q1 2022 | +7.7% | — | — | |
| Q4 2021 | +7.0% | — | — | |
| Q3 2021 | -10.1% | — | — | |
| Q2 2021 | +4.9% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | -6.6% | — | — | |
| Q3 2020 | +2.0% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | -4.0% | — | — | |
| Q4 2019 | +52.7% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +10.1% | — | — | |
| Q1 2019 | +0.6% | — | — | |
| Q4 2018 | -4.8% | — | — | |
| Q3 2018 | +1.2% | — | — | |
| Q2 2018 | +2.9% | — | — | |
| Q1 2018 | +29.2% | — | — | |
| Q4 2017 | -6.7% | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro